ArriVent BioPharma, Inc.
AVBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868279
No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding ArriVent BioPharma, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 54 | 1 | 68 | +15 |
| Shares | 21.7M | 663.3K | 25.9M | +4.92M (+23.4%) |
| Value | $404.2M | $12.3M | $612.3M | +$220.4M (+56.2%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held ArriVent BioPharma, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 1,931,419 | $45.4M | 0.00% |
| Marshall Wace, LLP | 85,250 | $2.00M | 0.00% |
| Goldman Sachs Group Inc | 72,968 | $1.71M | 0.00% |
| Saturn V Capital Management LLC | 47,266 | $1.11M | 0.40% |
| Alliancebernstein L.P. | 28,200 | $662.7K | 0.00% |
| Deutsche Bank AG | 15,331 | $360.3K | 0.00% |
| SG Americas Securities, LLC | 11,927 | $280.0K | 0.00% |
| Qube Research & Technologies Ltd | 11,354 | $266.8K | 0.00% |
| Manufacturers Life Insurance Company, The | 10,234 | $240.5K | 0.00% |
| Rafferty Asset Management, LLC | 9,536 | $224.1K | 0.00% |
| Price T Rowe Associates Inc | 9,345 | $220.0K | 0.00% |
| D. E. Shaw & Co., Inc. | 8,775 | $206.2K | 0.00% |
| AQR Capital Management LLC | 8,657 | $203.4K | 0.00% |
| Capital Performance Advisors LLP | 67 | $1.57K | 0.00% |
| Sterling Capital Management LLC | 59 | $1.39K | 0.00% |
| Aster Capital Management (DIFC) Ltd | 44 | $1.03K | 0.00% |
| Ronald Blue Trust, Inc. | 39 | $723 | 0.00% |
Sold out (2)
Institutions that held ArriVent BioPharma, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Hidden Lake Asset Management LP | 37,121 | $688.6K |
| Walleye Capital LLC | 25,000 | $463.8K |
Not filed for Q3 2024 yet (1)
Institutions that held ArriVent BioPharma, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 663,265 | $12.3M |